Geoffroy M, Lemesle M, Kleinclauss A, Mazerbourg S, Batista L, Barberi-Heyob M, Bastogne T, Boireau W, Rouleau A, Dupommier D, Boisbrun M, Comoy C, Flament S, Grillier-Vuissoz I, Kuntz S

Int J Mol Sci. 2022 06 20;23(12):

Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study.

Clément A, Zaragori T, Filosa R, Ovdiichuk O, Beaumont M, Collet C, Roeder E, Martin B, Maskali F, Barberi-Heyob M, Pouget C, Doyen M, Verger A

Cancer Imaging. 2022 Mar 18;22(1):16

Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography.

Moussaron A, Jouan-Hureaux V, Collet C, Pierson J, Thomas N, Choulier L, Veran N, Doyen M, Arnoux P, Maskali F, Dumas D, Acherar S, Barberi-Heyob M, Frochot C

Molecules. 2021 Nov 30;26(23):

The detrimental invasiveness of glioma cells controlled by gadolinium chelate-coated gold nanoparticles.

Durand M, Lelievre E, Chateau A, Berquand A, Laurent G, Carl P, Roux S, Chazee L, Bazzi R, Eghiaian F, Jubreaux J, Ronde P, Barberi-Heyob M, Chastagner P, Devy J, Pinel S

Nanoscale. 2021 May 12;:

Terbium-Based AGuIX-Design Nanoparticle to Mediate X-ray-Induced Photodynamic Therapy.

Daouk J, Iltis M, Dhaini B, Béchet D, Arnoux P, Rocchi P, Delconte A, Habermeyer B, Lux F, Frochot C, Tillement O, Barberi-Heyob M, Schohn H

Pharmaceuticals (Basel). 2021 Apr 22;14(5):

In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines.

Clément A, Doyen M, Fauvelle F, Hossu G, Chen B, Barberi-Heyob M, Hirtz A, Stupar V, Lamiral Z, Pouget C, Gauchotte G, Karcher G, Beaumont M, Verger A, Lemasson B

NMR Biomed. 2021 Feb 17;:e4490

Growth-Inhibitory Effect of Chitosan-Coated Liposomes Encapsulating Curcumin on MCF-7 Breast Cancer Cells.

Hasan M, Elkhoury K, Belhaj N, Kahn C, Tamayol A, Barberi-Heyob M, Arab-Tehrany E, Linder M

Mar Drugs. 2020 Apr 17;18(4):

Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles.

Pramual S, Lirdprapamongkol K, Jouan-Hureaux V, Barberi-Heyob M, Frochot C, Svasti J, Niamsiri N

Eur J Pharm Biopharm. 2020 Feb 26;:

Multiscale Selectivity and in vivo Biodistribution of NRP-1Targeted Theranostic AGuIX Nanoparticles for PDT of Glioblastoma.

Gries M, Thomas N, Daouk J, Rocchi P, Choulier L, Jubréaux J, Pierson J, Reinhard A, Jouan-Hureaux V, Chateau A, Acherar S, Frochot C, Lux F, Tillement O, Barberi-Heyob M

Int J Nanomedicine. 2020 ;15:8739-8758

Radiation-Induced Mitotic Catastrophe Enhanced by Gold Nanoparticles: Assessment with a Specific Automated Image Processing Workflow.

Paquot H, Daouk J, Chateau A, Rétif P, Barberi-Heyob M, Pinel S

Radiat. Res.. 2019 Apr 25;:

Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment.

Pinel S, Thomas N, Boura C, Barberi-Heyob M

Adv. Drug Deliv. Rev.. 2018 Nov 7;:

AGuIX from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.

Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O

Br J Radiol. 2018 Sep 18;:20180365

Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1.

Gong C, Valduga J, Chateau A, Richard M, Pellegrini-Moïse N, Barberi-Heyob M, Chastagner P, Boura C

Oncotarget. 2018 Mar 16;9(20):15312-15325

Polymer-lipid-PEG hybrid nanoparticles as photosensitizer carrier for photodynamic therapy.

Pramual S, Lirdprapamongkol K, Svasti J, Bergkvist M, Jouan-Hureaux V, Arnoux P, Frochot C, Barberi-Heyob M, Niamsiri N

J. Photochem. Photobiol. B, Biol.. 2017 May;173:12-22

Molecular modelling, synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application.

Kamarulzaman EE, Vanderesse R, Gazzali AM, Barberi-Heyob M, Boura C, Frochot C, Shawkataly O, Aubry A, Wahab HA

J. Biomol. Struct. Dyn.. 2017 Jan;35(1):26-45

Proton MR Spectroscopy and Diffusion MR Imaging Monitoring to Predict Tumor Response to Interstitial Photodynamic Therapy for Glioblastoma.

Toussaint M, Pinel S, Auger F, Durieux N, Thomassin M, Thomas E, Moussaron A, Meng D, Plénat F, Amouroux M, Bastogne T, Frochot C, Tillement O, Lux F, Barberi-Heyob M

Theranostics. 2017 ;7(2):436-451

Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma.

Thomas E, Colombeau L, Gries M, Peterlini T, Mathieu C, Thomas N, Boura C, Frochot C, Vanderesse R, Lux F, Barberi-Heyob M, Tillement O

Int J Nanomedicine. 2017 ;12:7075-7088

Carbohydrate-based peptidomimetics targeting neuropilin-1: Synthesis, molecular docking study and in vitro biological activities.

Richard M, Chateau A, Jelsch C, Didierjean C, Manival X, Charron C, Maigret B, Barberi-Heyob M, Chapleur Y, Boura C, Pellegrini-Moïse N

Bioorg. Med. Chem.. 2016 Nov;24(21):5315-5325

Realtime Tracking of the Photobleaching Trajectory During Photodynamic Therapy.

Tylcz JB, Bastogne T, Bourguignon A, Frochot C, Barberi-Heyob M

IEEE Trans Biomed Eng. 2016 Oct;:

Realtime Tracking of the Photobleaching Trajectory During Photodynamic Therapy.

Tylcz JB, Bastogne T, Bourguignon A, Frochot C, Barberi-Heyob M

IEEE Trans Biomed Eng. 2016 Oct;:

Robustness Analysis of a Geant4-GATE Simulator for Nanoradiosensitizers Characterization.

Retif P, Bastogne T, Barberi-Heyob M

IEEE Trans Nanobioscience. 2016 Apr;15(3):209-17

A Model-based Method of Characterizing the Pharmacokinetics of Engineered Nanoparticles in Pilot Studies.

Tylcz JB, Bastogne T, Benachour H, Bechet D, Bullinger E, Garnier H, Barberi-Heyob M

IEEE Trans Nanobioscience. 2015 Apr 1.

Multifunctional ultrasmall nanoplatforms for vascular-targeted interstitial photodynamic therapy of brain tumors guided by real-time MRI.

Bechet D, Auger F, Couleaud P, Marty E, Ravasi L, Durieux N, Bonnet C, Plenat F, Frochot C, Mordon S, Tillement O, Vanderesse R, Lux F, Perriat P, Guillemin F, Barberi-Heyob M

Nanomedicine. 2015 Jan 30. pii: S1549-9634(15)00013-1

Nanoparticles for Radiation Therapy Enhancement: the Key Parameters.

Retif P, Pinel S, Toussaint M, Frochot C, Chouikrat R, Bastogne T, Barberi-Heyob M

Theranostics. 2015 Jun 11;5(9):1030-44

New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy.

Kamarulzaman EE, Gazzali AM, Acherar S, Frochot C, Barberi-Heyob M, Boura C, Chaimbault P, Sibille E, Wahab HA, Vanderesse R

Int J Mol Sci. 2015 Oct 12;16(10):24059-80

Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.

Chastagner P, Sudour H, Mriouah J, Barberi-Heyob M, Bernier-Chastagner V, Pinel S

Pharm Res. 2015 Jan;32(1):158-66

The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy.

Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, Cremillieux Y, Fries P, Coll JL, Rodriguez-Lafrasse C, Janier M, Dutreix M, Barberi-Heyob M, Boschetti F, Denat F, Louis C, Porcel E, Lacombe S, Le Duc G, Deutsch E, Perfettini JL, Detappe A, Verry C, Berbeco R, Butterworth KT, McMahon SJ, Prise KM, Perriat P, Tillement O

Br J Radiol. 2014 Sep;87(1041):20140134

Rational design of an arene ruthenium chlorin conjugate for in vivo anticancer activity.

Pernot M, Barry NPE, Bastogne T, Frochot C, Barberi-Heyob M, Therrien B

Inorg Chim Acta. 2014 Apr 1;414:134-40.

Photodynamic therapy of malignant brain tumours: a complementary approach to conventional therapies.

Bechet D, Mordon SR, Guillemin F, Barberi-Heyob MA

Cancer Treat Rev. 2014 Mar;40(2):229-41

Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation.

Hasan M, Belhaj N, Benachour H, Barberi-Heyob M, Kahn CJ, Jabbari E, Linder M, Arab-Tehrany E

Int J Pharm. 2014 Jan 30;461(1-2):519-28

Preparation and characterization of mTHPC-loaded solid lipid nanoparticles for photodynamic therapy.

Navarro FP, Creusat G, Frochot C, Moussaron A, Verhille M, Vanderesse R, Thomann JS, Boisseau P, Texier I, Couffin AC, Barberi-Heyob M

J Photochem Photobiol B. 2014 Jan 5;130:161-9

X-ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins.

Bulin AL, Truillett C, Chouikrat R, Lux F, Frochot C, Amans D, Ledoux G, Tillement O, Perriat P, Barberi-Heyob M, Dujardin C

J Phys Chem C. 2013 Oct 17;117(41):21583-9.

Bifunctional polypyridyl-Ru(II) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy.

Truillet C, Lux F, Moreau J, Four M, Sancey L, Chevreux S, Boeuf G, Perriat P, Frochot C, Antoine R, Dugourd P, Portefaix C, Hoeffel C, Barberi-Heyob M, Terryn C, van Gulick L, Lemercier G, Tillement O

Dalton Trans. 2013 Sep 14;42(34):12410-20

Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds.

Pernot M, Bastogne T, Barry NP, Therrien B, Koellensperger G, Hann S, Reshetov V, Barberi-Heyob M

J Photochem Photobiol B. 2012 Dec 5;117:80-9

Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models.

Mriouah J, Boura C, Thomassin M, Bastogne T, Dumas D, Faivre B, Barberi-Heyob M

Trends Biotechnol. 2012 Dec;30(12):649-58

Limits of variance-based sensitivity analysis for non-identifiability testing in high dimensional dynamic models.

Dobre S, Bastogne T, Profeta C, Barberi-Heyob M, Richard A

. 2012 Nov;48(11):2740-9.

Non polymeric nanoparticles for photodynamic therapy applications: recent developments.

Chouikrat R, Seve A, Vanderesse R, Benachour H, Barberi-Heyob M, Richeter S, Raehm L, Durand JO, Verelst M, Frochot C

Mini Rev Med Chem. 2012 Sep 7.

Multifunctional Peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI.

Benachour H, Seve A, Bastogne T, Frochot C, Vanderesse R, Jasniewski J, Miladi I, Billotey C, Tillement O, Lux F, Barberi-Heyob M

Theranostics. 2012;2(9):889-904

Non polymeric nanoparticles for photodynamic therapy applications: recent developments.

Chouikrat R, Seve A, Vanderesse R, Benachour H, Barberi-Heyob M, Richeter S, Raehm L, Durand JO, Verelst M, Frochot C

Curr Med Chem. 2012;19(6):781-92.

Photodynamic molecular beacons triggered by MMP-2 and MMP-9: influence of the distance between photosensitizer and quencher onto photophysical properties and enzymatic activation.

Verhille M, Benachour H, Ibrahim A, Achard M, Arnoux P, Barberi-Heyob M, Andre JC, Allonas X, Baros F, Vanderesse R, Frochot C

Curr Med Chem. 2012;19(32):5580-94.

Real-time monitoring of photocytotoxicity in nanoparticles-based photodynamic therapy: a model-based approach.

Benachour H, Bastogne T, Toussaint M, Chemli Y, Seve A, Frochot C, Lux F, Tillement O, Vanderesse R, Barberi-Heyob M

PLoS One. 2012;7(11):e48617

In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells.

Mowat P, Mignot A, Rima W, Lux F, Tillement O, Roulin C, Dutreix M, Bechet D, Huger S, Humbert L, Barberi-Heyob M, Aloy MT, Armandy E, Rodriguez-Lafrasse C, Le Duc G, Roux S, Perriat P

J Nanosci Nanotechnol. 2011 Sep;11(9):7833-9.

Functionalized silica-based nanoparticles for photodynamic therapy.

Couleaud P, Bechet D, Vanderesse R, Barberi-Heyob M, Faure AC, Roux S, Tillement O, Porhel S, Guillemin F, Frochot C

Nanomedicine (Lond). 2011 Aug;6(6):995-1009

Stability of peptides and therapeutic success in cancer.

Pernot M, Vanderesse R, Frochot C, Guillemin F, Barberi-Heyob M

Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):793-802

Quantum dot-folic acid conjugates as potential photosensitizers in photodynamic therapy of cancer.

Morosini V, Bastogne T, Frochot C, Schneider R, Francois A, Guillemin F, Barberi-Heyob M

Photochem Photobiol Sci. 2011 May;10(5):842-51

Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy.

Verhille M, Couleaud P, Vanderesse R, Brault D, Barberi-Heyob M, Frochot C

Curr Med Chem. 2010;17(32):3925-43.

Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties.

Thomas N, Pernot M, Vanderesse R, Becuwe P, Kamarulzaman E, Da Silva D, Francois A, Frochot C, Guillemin F, Barberi-Heyob M

Biochem Pharmacol. 2010 Jul 15;80(2):226-35

Sugar-based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1.

Novoa A, Pellegrini-Moise N, Bechet D, Barberi-Heyob M, Chapleur Y

Bioorg Med Chem. 2010 May 1;18(9):3285-98

Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release.

Bechet D, Tirand L, Faivre B, Plenat F, Bonnet C, Bastogne T, Frochot C, Guillemin F, Barberi-Heyob M

Pharm Res. 2010 Mar;27(3):468-79

Phenomenological modeling of tumor diameter growth based on a mixed effects model.

Bastogne T, Samson A, Vallois P, Wantz-Mezieres S, Pinel S, Bechet D, Barberi-Heyob M

J Theor Biol. 2010 Feb 7;262(3):544-52

Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions.

Tirand L, Bastogne T, Bechet D, Linder M, Thomas N, Frochot C, Guillemin F, Barberi-Heyob M

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):244-52

Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo.

Thomas N, Bechet D, Becuwe P, Tirand L, Vanderesse R, Frochot C, Guillemin F, Barberi-Heyob M

J Photochem Photobiol B. 2009 Aug 3;96(2):101-8

Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts

Labussiere M, Aarnink A, Pinel S, Taillandier L, Escanye JM, Barberi-Heyob M, Bernier-Chastagner V, Plenat F, Chastagner P

Anticancer Drugs. 2008 Nov;19(10):991-8.

Nanoparticles as vehicles for delivery of photodynamic therapy agents

Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M

Trends Biotechnol. 2008 Nov;26(11):612-21

Advantages and limitations of commonly used methods to assay the molecular permeability of gap junctional intercellular communication.

Abbaci M, Barberi-Heyob M, Blondel W, Guillemin F, Didelon J

Biotechniques. 2008 Jul;45(1):33-52, 56-62.

Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies.

Gravier J, Schneider R, Frochot C, Bastogne T, Schmitt F, Didelon J, Guillemin F, Barberi-Heyob M

J Med Chem. 2008 Jul 10;51(13):3867-77

Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice.

Thomas N, Tirand L, Chatelut E, Plenat F, Frochot C, Dodeller M, Guillemin F, Barberi-Heyob M

Photochem Photobiol Sci. 2008 Apr;7(4):433-41

Identification of pharmacokinetics models in the presence of timing noise

Bastogne T, Mezieres-Wantz S, Ramdani N, Vallois P, Barberi-Heyob M

Eur J Control. 2008 Mar-apr;14(2):149-57

System identification of photosensitiser uptake kinetics in photodynamic therapy

Bastogne T, Tirand L, Bechet D, Barberi-Heyob M, Richard A

Biomed Signal Process Control. 2007 Jul;2(3):217-25

Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity.

Frochot C, Di Stasio B, Vanderesse R, Belgy MJ, Dodeller M, Guillemin F, Viriot ML, Barberi-Heyob M

Bioorg Chem. 2007 Jun;35(3):205-20

Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study.

Tirand L, Thomas N, Dodeller M, Dumas D, Frochot C, Maunit B, Guillemin F, Barberi-Heyob M

Drug Metab Dispos. 2007 May;35(5):806-13

The photodynamic therapy

Barberi-Heyob M, Frochot C, Bezdetnaya-Bolotine L, Brault D, Dumas D, Guillemin F, Krausz P, Maillard P, Maunit B, Merlin JL, Mordon S, Muller JF, Patrice T, Simonneaux G, Tanielian C

Actual Chim. 2007 May-jun;:26-34

Gap junctional intercellular communication capacity by gap-FRAP technique: a comparative study.

Abbaci M, Barberi-Heyob M, Stines JR, Blondel W, Dumas D, Guillemin F, Didelon J

Biotechnol J. 2007 Jan;2(1):50-61.

Practical identifiability of photophysical parameters in photodynamic therapy.

Dobre S, Bastogne T, Barberi-Heyob M, Richard A

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:6633-6.

Divergent synthesis of novel unsymmetrical dendrons containing photosensitizing units.

Morosini V, Frochot C, Barberi-Heyob M, Schneider R

Tetrahedron Lett. 2006 Dec 4;47(49):8745-9.

Recent improvements in the use of synthetic peptides for a selective photodynamic therapy.

Schneider R, Tirand L, Frochot C, Vanderesse R, Thomas N, Gravier J, Guillemin F, Barberi-Heyob M

Anticancer Agents Med Chem. 2006 Sep;6(5):469-88.

A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.

Tirand L, Frochot C, Vanderesse R, Thomas N, Trinquet E, Pinel S, Viriot ML, Guillemin F, Barberi-Heyob M

J Control Release. 2006 Mar 10;111(1-2):153-64

The 2-aminoglucosamide motif improves cellular uptake and photodynamic activity of tetraphenylporphyrin.

Di Stasio B, Frochot C, Dumas D, Even P, Zwier J, Muller A, Didelon J, Guillemin F, Viriot ML, Barberi-Heyob M

Eur J Med Chem. 2005 Nov;40(11):1111-22

Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy.

Schneider R, Schmitt F, Frochot C, Fort Y, Lourette N, Guillemin F, Muller JF, Barberi-Heyob M

Bioorg Med Chem. 2005 Apr 15;13(8):2799-808.

Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.

Pinel S, Barberi-Heyob M, Cohen-Jonathan E, Merlin JL, Delmas C, Plenat F, Chastagner P

Int. J. Radiat. Oncol. Biol. Phys.. 2004 May;59(1):250-9

Wild-type p53 gene transfer into mutated p53 HT29 cells improves sensitivity to photodynamic therapy via induction of apoptosis.

Barberi-Heyob M, Vedrine PO, Merlin JL, Millon R, Abecassis J, Poupon MF, Guillemin F

Int J Oncol. 2004 Apr;24(4):951-8.

Arachidonic acid activates a functional AP-1 and an inactive NF-kappaB complex in human HepG2 hepatoma cells.

Bécuwe P, Bianchi A, Didelot C, Barberi-Heyob M, Dauça M

Free Radic. Biol. Med.. 2003 Sep;35(6):636-47

Oncoprotein expression of E6 and E7 does not prevent 5-fluorouracil (5FU) mediated G1/S arrest and apoptosis in 5FU resistant carcinoma cell lines.

Didelot C, Mirjolet JF, Barberi-Heyob M, Ramacci C, Teiten MH, Merlin JL

Int. J. Oncol.. 2003 Jul;23(1):81-7

The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cells.

Merlin JL, Gautier H, Barberi-Heyob M, Teiten MH, Guillemin F

Int. J. Oncol.. 2003 Apr;22(4):733-9

New glycosylated porphyrins for PDT applications.

Frochot C, Di Stasio B, Barberi-Heyob M, Carre MC, Zwier JM, Guillemin F, Viriot ML

Oftalmologia. 2003 ;56(1):62-6

In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.

Merlin JL, Barberi-Heyob M, Bachmann N

Ann Oncol. 2002 Nov;13(11):1743-8.

In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector.

Dolivet G, Merlin JL, Barberi-Heyob M, Ramacci C, Erbacher P, Parache RM, Behr JP, Guillemin F

Cancer Gene Ther.. 2002 Aug;9(8):708-14

Radiation could induce p53-independent and cell cycle--unrelated apoptosis in 5-fluorouracil radiosensitized head and neck carcinoma cells.

Didelot C, Mirjolet JF, Barberi-Heyob M, Ramacci C, Merlin JL

Can. J. Physiol. Pharmacol.. 2002 Jul;80(7):638-43

G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.

Mirjolet JF, Didelot C, Barberi-Heyob M, Merlin JL

Cytometry. 2002 May;48(1):6-13

Constitutive NF-kappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines.

Didelot C, Barberi-Heyob M, Bianchi A, Becuwe P, Mirjolet JF, Dauça M, Merlin JL

Int. J. Radiat. Oncol. Biol. Phys.. 2001 Dec;51(5):1354-60

Pharmacokinetic longitudinal studies of antibiotics administered via a permanent intraosseous device in micropigs.

Chastagner P, Lozniewski A, Lascombes P, Barberi-Heyob M, Merthes PM, Merlin JL

Med. Pediatr. Oncol.. 2001 Jun;36(6):635-40

Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.

Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, Merlin JL

Br. J. Cancer. 2000 Nov;83(10):1380-6

In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice.

Chastagner P, Merlin JL, Marchal C, Hoffstetter S, Barberi-Heyob M, Vassal G, Duprez A

Clin. Cancer Res.. 2000 Aug;6(8):3327-33

Intracellular distribution of tamoxifen in resistant human breast adenocarcinoma cells using tamoxifen-eosin association.

Bachmann N, Barberi-Heyob M, Bour C, Parache RM, Guillemin F, Batt AM, Merlin JL

Cell Biol. Toxicol.. 1998 Dec;14(6):429-35

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Rivière A, Perrocheau G, Etienne MC, Milano G

Clin. Cancer Res.. 1998 Sep;4(9):2039-45

Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity.

Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G, Bey P

Br. J. Cancer. 1998 Jul;78(1):62-8

Sensitive isocratic liquid chromatographic assay for the determination of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin in plasma and tissue with electrochemical detection.

Barberi-Heyob M, Rezzoug H, Merlin JL, Guillemin F

J. Chromatogr. B Biomed. Sci. Appl.. 1997 Jan;688(2):331-8

[Molecular aspects of different mechanisms of tamoxifen resistance].

Bachmann-Moisson N, Barberi-Heyob M, Merlin JL

Bull Cancer. 1997 Jan;84(1):69-75

[Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].

Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F

Bull Cancer. 1996 Oct;83(10):808-15

[In vitro comparison of the photodynamic activity of meso-tetra (m-hydroxyphenyl) chlorin and hematoporphyrin derivative].

Rezzoug H, Barberi-Heyob M, Merlin JL, Bolotine L, Lignon D, Guillemin F

Bull Cancer. 1996 Oct;83(10):816-22

Spectroscopic and biological testing of photobleaching of porphyrins in solutions.

Bezdetnaya L, Zeghari N, Belitchenko I, Barberi-Heyob M, Merlin JL, Potapenko A, Guillemin F

Photochem. Photobiol.. 1996 Aug;64(2):382-6

[Stability of 5-fluorouracil solutions according to different parameters].

Barberi-Heyob M, Watelet M, Merlin JL, Bleger C, Schroeder B

Bull Cancer. 1995 Dec;82(12):1025-31

Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.

Barberi-Heyob M, Merlin JL, Vigneron M, Conroy T

Anticancer Drugs. 1995 Feb;6(1):163-4

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Barberi-Heyob M, Weber B, Merlin JL, Dittrich C, de Bruijn EA, Luporsi E, Guillemin F

Cancer Chemother. Pharmacol.. 1995 ;37(1-2):110-6

[Plasma pharmacokinetics of morphine and morphine-6-glucuronide using high performance liquid chromatography and colorimetric detection].

Barberi-Heyob M, Merlin JL, Krakowski I, Kettani C, Collin E, Poulain P

Bull Cancer. 1991 Nov;78(11):1063-70

Sensitive determination of free and plasma protein-bound dipyridamole by high-performance liquid chromatography.

Barberi M, Merlin JL, Weber B

J. Chromatogr.. 1991 Apr;565(1-2):511-5

Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results.

Fety R, Rolland F, Barberi-Heyob M, Merlin JL, Conroy T, Hardouin A, Riviere A, Milano G

Anticancer Res.. ;14(6A):2347-52

Monte Carlo simulations guided by imaging to predict the in vitro ranking of radiosensitizing nanoparticles.

Retif P, Reinhard A, Paquot H, Jouan-Hureaux V, Chateau A, Sancey L, Barberi-Heyob M, Pinel S, Bastogne T

Int J Nanomedicine. ;11:6169-6179